Reduced α-Dystroglycan Expression Correlates with Shortened Patient Survival in Pancreatic Cancer

Jiang, Xiaohua; Rieder, Simon; Giese, Nathalia A.; Friess, Helmut; Michalski, Christoph; Kleeff, Jörg

doi:10.1016/j.jss.2009.11.730

Cited by 16 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The difference of β-DG expression between each group was statistically significant except for groups between metastatic lymph node and distal metastatic site. Regarding the relationship between β-DG and patients survival, the difference of β-DG expression between tumor and normal tissues was not associated with patient survival, this result was the same as reported by Jiang XJ et al [17], who demonstrated that the median survival time in patients with low expression of β-DG was not significantly different as compared to the patients with high expression of β-DG in pancreatic cancer.…”

Section: Discussionsupporting

confidence: 86%

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

Shen

et al. 2011

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Previous reports had indicated that there was a possible correlation of dystroglycan (DG) with biological behavior of cancer cells and cancer patients' survival. However, the role of DG expression in gastric cancer was rarely studied. In this study, α-DG and β-DG expression were determined by immunohistochemistry in specimens of primary cancer, metastatic lymph node, distal metastatic lesion, and their normal counterpart tissues in 20 gastric cancer patients. Correlations between α-DG and β-DG expression and prognosis were retrospectively analyzed. Our results found that positive expression of α-DG in normal mucosa, paired primary tumor, metastatic lymph node and distal metastatic site was detected in 95%, 70%, 25%, and 5% specimens, individually. Regarding β-DG,it was 70%, 55%, 10%, and 10%, individually. Patients who had lower α-DG expression in tumors than in normal counterparts showed poor survival (p = 0.002), whereas such a correlation was not found in the case of β-DG (p = 0.079). Difference of α-DG between primary tumor and its normal counterparts was an independent prognostic factor in gastric cancer with distal metastasis. This study showed DG expression was gradually reduced during tumor progression. Different expression of α-DG, but not β-DG, between primary tumor and normal specimen, correlated with patient survival, implicating a potential marker for gastric cancer prognosis.

show abstract

Section: Discussionsupporting

confidence: 86%

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

Shen

et al. 2011

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Consistent with the idea that ␣DG hypoglycosylation is associated with a more aggressive disease phenotype, hypoglycosylation of ␣DG has, in some small retrospective studies, demonstrated potential prognostic value in predicting disease recurrence or survival (54,(57)(58)(59)(60). Prior work in prostate cancer demonstrated that ␣DG hypoglycosylation is associated with increasing Gleason score (46,47).…”

Section: Discussionmentioning

confidence: 71%

Loss of LARGE2 Disrupts Functional Glycosylation of α-Dystroglycan in Prostate Cancer

Esser

Miller

Huang

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Dystroglycan function is decreased in prostate and other cancers. Results: Decreased functional glycosylation of ␣-dystroglycan is clinically correlated with reduced LARGE2 and restoring its expression rescues dystroglycan function, reducing the invasive and proliferative potential of prostate cancer cells. Conclusion: LARGE2 regulates ␣-dystroglycan function in the prostatic epithelium. Significance: Loss of LARGE2 expression may contribute to prostate cancer progression.

show abstract

“…Staining scores for these markers were calculated by multiplying the staining intensity score (0 = no staining, 1 = weak or moderate, 2 = strong) in a given tumoral area by the stained area score (1< one‐third, 2 = between one‐ and two‐thirds, 3> two‐thirds) as previously described 17. The total immunohistochemical score (0–6) was expressed as the product of the intensity and area scores.…”

Section: Methodsmentioning

confidence: 99%

Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma

Conesa‐Zamora

García‐Solano

García‐García

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

Serrated adenocarcinoma (SAC) is a recently recognized colorectal cancer (CRC) subtype accounting for 7.5 to 8.7% of CRCs. It has been shown that SAC has a poorer prognosis and has different molecular and immunohistochemical features compared with conventional carcinoma (CC) but, to date, only one previous study has analyzed its mRNA expression profile by microarray. Using a different microarray platform, we have studied the molecular signature of 11 SACs and compared it with that of 15 matched CC with the aim of discerning the functions which characterize SAC biology and validating, at the mRNA and protein level, the most differentially expressed genes which were also tested using a validation set of 70 SACs and 70 CCs to assess their diagnostic and prognostic values. Microarray data showed a higher representation of morphogenesis-, hypoxia-, cytoskeleton-and vesicle transport-related functions and also an overexpression of fascin1 (actin-bundling protein associated with invasion) and the antiapoptotic gene hippocalcin in SAC all of which were validated both by quantitative real-time PCR (qPCR) and immunohistochemistry. Fascin1 expression was statistically associated with KRAS mutation with 88.6% sensitivity and 85.7% specificity for SAC diagnosis and the positivity of fascin1 or hippocalcin was highly suggestive of SAC diagnosis (sensitivity 5 100%). Evaluation of these markers in CRCs showing histological and molecular characteristics of high-level microsatellite instability (MSI-H) also helped to distinguish SACs from MSI-H CRCs. Molecular profiling demonstrates that SAC shows activation of distinct signaling pathways and that immunohistochemical fascin1 and hippocalcin expression can be reliably used for its differentiation from other CRC subtypes.

show abstract

Reduced α-Dystroglycan Expression Correlates with Shortened Patient Survival in Pancreatic Cancer

Cited by 16 publications

References 27 publications

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

Loss of LARGE2 Disrupts Functional Glycosylation of α-Dystroglycan in Prostate Cancer

Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma

Contact Info

Product

Resources

About